Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results, Provides Recent Business Highlights

• Positive initial data announced from Phase 1 study of TIDAL-01 in metastatic colorectal cancer, including complete response in one of four patients reported
• The cash position is expected to finance operations through the third quarter of 2025

SAN DIEGO, August 14, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX)a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors through breakthrough therapy using Selected Tumor Infiltrating Lymphocytes (Selected TIL), today reported financial results for the second quarter ended June 30, 2024 and also provided recent business highlights.

“We further strengthened our position by advancing our pipeline and business in the second quarter of 2024. This includes reporting encouraging initial data from our Phase 1 study of TIDAL-01 in patients with metastatic colorectal cancer,” said Sammy Farah, MBA, Ph.D., Turnstone’s President and Chief Executive Officer. “The clinical signals from these initial data, including a remarkable complete response in one of the first four patients, demonstrated deep and durable anti-tumor activity, along with accompanying biological data, supporting our fundamental hypothesis of enrichment for tumor-reactive T cells in our select TIL therapies. As the competitive profile of TIDAL-01 strengthens with these initial clinical data, we are prioritizing development in solid tumor indications, including metastatic colorectal cancer, where we believe we can differentiate our TIL technology and provide the greatest benefit to patients.”